Results 71 to 80 of about 213,637 (257)

Asymmetric Structure‐Driven Functional Synergy: A Multistimuli‐Activated Janus Nanomotor for Self‐Amplifying NO Cascade Therapy

Advanced Science, EarlyView.
The Janus nanomotors leverage an “asymmetric structure‐driven functional synergy” strategy to orchestrate spatiotemporally coordinated catalytic functions, in situ self‐amplifying NO generation, and deep tumor penetration, thereby enabling controllable, sustained, and uniform NO generation within the tumor microenvironment.
Chengcheng Li, Yu Zhang, Yu Chen, Lingyun He, Xian Shen, Weijian Sun, Hongbo Zhang   +6 more
wiley   +1 more source

Paclitaxel-activated astrocytes produce mechanical allodynia in mice by releasing tumor necrosis factor-α and stromal-derived cell factor 1

Journal of Neuroinflammation, 2019
Background Paclitaxel is a widely used and potent chemotherapeutic agent for the treatment of cancer. However, patients receiving paclitaxel often develop an acute pain syndrome for which there are few treatment options. Astrocytes play an important role
Xiaojuan Liu, Raquel Tonello, Yuejuan Ling, Yong-Jing Gao, Temugin Berta   +4 more
doaj   +1 more source

Comparative effectiveness of early-line nab-paclitaxel vs. paclitaxel in patients with metastatic breast cancer: a US community-based real-world analysis

, 2018
Reshma L Mahtani,1 Monika Parisi,2 Stefan Glück,3 Quanhong Ni,2 Siyeon Park,4 Corey Pelletier,2 Claudio Faria,2 Fadi Braiteh5,6 1Division of Hematology/Oncology, University of Miami, Miami, FL, 2Health Economics and Outcomes Research, Celgene ...
Glück S, Faria C, Braiteh F, Mahtani RL, Ni Q, Parisi M, Pelletier C, Park S   +7 more
core  

Successful treatment with nab-paclitaxel after hypersensitivity reaction to paclitaxel and docetaxel [PDF]

, 2013
* First case report of successfully treating severe paclitaxel and docetaxel hypersensitivity reaction with nab-paclitaxel. * We demonstrated that nab-paclitaxel is a safe taxane chemotherapy treatment option for patients who could not tolerate ...
Greene, Barbra, Del Priore, Giuseppe, Bolla, Sridhar, de Leon, Maria C. B., Hutchinson, Lauren   +4 more
core   +1 more source

Molecular Landscapes of Tumor Dormancy in Gynecologic Malignancies: From Survival Mechanisms to Precision Interception

Advanced Science, EarlyView.
This Review outlines the biological framework of entry, maintenance, and awakening in dormant minimal residual disease across gynecologic cancers. By mapping critical biological dependencies—from metabolic plasticity to microenvironment interactions—it evaluates novel interception concepts and presents a translational framework combining single‐cell ...
Shih‐Hsuan Cheng, Ren‐Wang Peng, Chang‐Cheng Wu, Chi‐Wen Luo, Emmanuel Naveen Raj, Zhi‐Hong Wen, Tzu‐Hung Hsiao, Chia‐Jung Li   +7 more
wiley   +1 more source

Targeting CDK8 dually enhances paclitaxel antitumor efficacy and alleviates chemotherapy-induced peripheral neuropathy in breast cancer

Frontiers in Pharmacology
BackgroundPaclitaxel-based chemotherapy remains a mainstay for breast cancer treatment, yet its efficacy is often limited by drug resistance and dose-limiting peripheral neuropathy.
Xuejiao Hong, Xuejiao Hong, Dong Fang
doaj   +1 more source

CXCL3 Antagonism Reverses Systemic Antitumor Immune Memory Impairment Associated With High Tumor Burden and Sensitizes Anti‐PD‐1 Therapy

Advanced Science, EarlyView.
This study reveals that large tumors secrete more chemokine CXCL3, which recruits immunosuppressive neutrophils to the periphery, thereby impairing the activation and memory of systemic tumor‑reactive CD8+ T cells. CXCL3 antagonism restores systemic immune memory and enhances the antitumor efficacy of anti‑PD‑1 therapy, offering a potential strategy to
Ji Wang, Xinyu Tang, Zeju Li, Qi Qi, Chang Sun, Wen Sun, Weiya Zhang, Yue Yin, Ya Deng, Peiwen Ling, Yifan Xu, Guangshun Sun, Yi Ren, Hong Pan, Shui Wang, Wenbin Zhou   +15 more
wiley   +1 more source

Targeting Macrophage‐Mediated Lymphatic Immunosuppression to Prevent Tumor Recurrence After Microwave Ablation

Advanced Science, EarlyView.
Incomplete microwave ablation induces animmunosuppressive microenvironment in tumor‐draining lymph nodes. An albumin‐based lipoprotein nanosystem enables coordinated delivery of immunomodulators to tumor‐draining lymph nodes and residual tumors, reverses post‐ablation immunosuppression, suppresses residual tumor growth, and promotes durable antitumor ...
Xuexia Shan, Yuting Shen, Xiaodong Hou, Fengshan Jin, Shaoyue Li, Weichen Xu, Weiwei Ren, Xiaowan Bo, Qiuyan Li, Shuo Liu, Weifan Hao, Chengzhong Peng, Huixiong Xu, Liping Sun, Wenwen Yue   +14 more
wiley   +1 more source

Table_1_nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC.docx

, 2018
The phase 4 ABOUND.70+ trial assessed the safety and efficacy of nab-paclitaxel/carboplatin continuously or with a 1-week break between cycles in elderly patients with advanced non-small cell lung cancer (NSCLC).
Matei P. Socoteanu (5546894), Teng J. Ong (5546897), Manuel Modiano (5546885), Kartik Konduri (5546879), Eric C. Anderson (3073926), Jonathan W. Goldman (5546906), on behalf of the ABOUND.70+ Investigators (5546903), Daniel E. Haggstrom (5546888), Edward S. Kim (2183847), Corey J. Langer (5546882), Robert M. Jotte (5546891), Tymara Berry (5546843), Jared Weiss (5546900), Christopher Dakhil (5546876), Alexandra Sanford (5546849), Katayoun Amiri (5546870), David A. Smith (2577271)   +16 more
core   +1 more source

Long Non-coding RNA CDKN2B Antisense RNA 1 Gene Contributes to Paclitaxel Resistance in Endometrial Carcinoma

Frontiers in Oncology, 2019
Endometrial cancer (EC) is the most common malignancy of the female reproductive tract. In this study, we clarified the clinical significance of CDKN2B antisense RNA 1 (CDKN2B-AS) gene, and its effects on paclitaxel sensitivity in EC.
Chao Shang, Cheng N. Ao, Chi C. Cheong, Lirong Meng   +3 more
doaj   +1 more source